11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, CA
Annual Report to Security Holders
Amended material disclosure
Stock Option Repricing Approved for Skye Bioscience Executives
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CFO Departure - Kaitlyn Arsenault Steps Down with $450,000 Severance
Investor Presentation
Skye Bioscience Enters Non-Exclusive Agreement with Halozyme for Drug Delivery
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Definitive Information Statement
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Amended Initial Statement of Beneficial Ownership
PREM14A
Submission Upload
Correspondence
Amended Schedule 13D - Ownership Report